AMPE News and Press, Ampio Pharmaceuticals Inc. From 04/21/22

Ampio Pharmaceuticals' (NYSE:AMPE) said the U.S. Food and Drug Administration (FDA) did not agree with proposed changes made to a phase 3 trial for pain drug Ampion and that the company should have sought the regulator's nod before unblinding the data. The company was evaluatin...

AMPIO PROVIDES REGULATORY UPDATE PR Newswire ENGLEWOOD, Colo. , April 20, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment o...

Ampio Pharmaceuticals, Inc. (AMPE) Q4 2021 Earnings Conference Call March 29, 2022 04:30 AM ET Company Participants Michael Martino - Chairman and Chief Executive Officer Dan Stokely - CFO Holli Cherevka - President and COO Howard Levy - Chief Medical Officer Nicolas Johnson - Russo Partners,...

Ampio Pharmaceuticals press release (NYSE:AMPE): Q4 GAAP EPS of -$0.10. Cash and cash equivalents on December 31, 2021, totaled $33.9 million, compared to $17.3 million as of December 31, 2020, Shares +2.1%. For further details see: Ampio Pharmaceuticals GAAP EPS of -$0.10

Ampio Pharmaceuticals Reports Fourth-Quarter and Full-Year 2021 Financial Results and Operational Highlights PR Newswire Cash and Cash Equivalents of $34 Million Expected to Fund Current Operations into 2H 2023 Company to host Conference Call Tuesda...

Ampio Pharmaceuticals (NYSE:AMPE) is scheduled to announce Q4 earnings results on Tuesday, March 29th, after market close. The consensus EPS Estimate is -$0.02 (+77.8% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 0 upward revisions a...

AMPE, AREC, CALM, CHWY, CRMD, CWBR, CWCO, HTGM, INFI, OTCQB:LQMT, LULU, MLKN, MOTS, MU, MVST, NBRV, NBY, OTC:OIBZQ, OPGN, PAVM, PRGS, PVH, RH, SNDL, SPWH, SUNL, VRNT, ZVO For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Tuesd...

Ampio Pharmaceuticals, Inc. to Hold Fourth Quarter 2021 Earnings and Business Update Call PR Newswire ENGLEWOOD, Colo. , March 23, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the ...

Ampio Pharmaceuticals to Participate at the 34th Annual Roth Conference Moderated fireside chat will be held Tuesday, March 15 at 4:30pm ET PR Newswire ENGLEWOOD, Colo. , March 9, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a b...

Ampio Pharmaceuticals, Inc. Releases Positive Phase 3 Data Analysis for Ampion™ Targeting Severe Osteoarthritis of the Knee (OAK) Complete analysis of AP-013 data show Ampion reduced pain with statistical significance The U.S. Food and Drug Administration has Confirme...